Oncology Central

Phase III IMpower133 study has met its co-primary OS and PFS endpoints

1
It has been announced that the Phase III IMpower133 study has met its co-primary endpoints of overall survival (OS) and progression-free survival (PFS) at its first interim analysis.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

1 Comment

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.